Biogen CEO sees edge over Lilly with at-home Alzheimer’s drug

Biogen Inc.’s new at-home Alzheimer’s drug will give the company an edge over rival Eli Lilly Co.’s competing therapy, its chief executive officer said in an interview.

Biogen CEO Says New Drugs Offset MS Decline, Eyes 2026 “Transformational Era” at JPMorgan Conference

CEO Chris Viehbacher told investors the company has worked to stabilize its business as its multiple sclerosis (MS) portfolio continues to decline, while building new growth drivers and reshaping its ...

Biogen CEO Chris Viehbacher on 2026 drug pipeline outlook, rare disease strategy

Biogen CEO Chris Viehbacher joins 'Squawk Box' to discuss the company's 2026 outlook, drug pipeline, the focus on rare diseases, state of the biotech sector, and more.
The Business Journals

Biogen on the hunt for acquisition after $1B in cuts, 15% workforce reduction

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Biogen's CEO says the company's ...
CSR Wire

Biogen Leads From the Top With Disability Inclusion

December 3rd marks International Day of Persons with Disabilities, and we are glad to share that Biogen CEO Michel Vounatsos recently signed the Disability:IN’s CEO Letter on Disability Inclusion. We ...